Tolmar Inc.
Clinical trials sponsored by Tolmar Inc., explained in plain language.
-
Breast cancer drug safety tracked for 4 years in extension study
Disease control ENROLLING_BY_INVITATIONThis study is for people with HR+, HER2- breast cancer who finished a previous study on TOL2506. It aims to check the long-term safety of TOL2506 when taken with tamoxifen or an aromatase inhibitor for up to 4 years. About 250 premenopausal women and men will take part. The main …
Phase: PHASE3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New injection could help premenopausal women fight breast cancer
Disease control OngoingThis phase 3 study tests a 3-month injection (TOL2506) to temporarily stop ovarian function in premenopausal women with HR+, HER2- breast cancer. The goal is to lower hormones that can fuel cancer growth. About 250 participants will receive the injection along with standard hormo…
Phase: PHASE3 • Sponsor: Tolmar Inc. • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New study checks if testosterone drug JATENZO impacts adrenal glands
Knowledge-focused OngoingThis study looks at whether JATENZO, a testosterone replacement therapy, affects adrenal function in men with low testosterone (hypogonadism). About 110 men aged 18 to 65 will take JATENZO for 12 months. Researchers will measure cortisol levels after a stimulation test to see if …
Phase: PHASE4 • Sponsor: Tolmar Inc. • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC